Question · asked by 1 review
Amifostine vs no treatment/placebo: Salivary flow rate
- Population
- Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
- Intervention
- Amifostine
- Comparison
- no treatment/placebo
- Outcome
- Salivary flow rate
Amifostine led to higher salivary flow rate (incidence of > 0.1 g saliva/5 min, unstimulated) compared with no treatment/placebo; GRADE not reported.
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Amifostine vs No treatment/placebo Salivary flow rate (incidence of > 0.1 g saliva/5 min, unstimulated) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region · 12 months postRT Amifostine led to higher salivary flow rate (incidence of > 0.1 g saliva/5 min, unstimulated) compared with no treatment/placebo; GRADE not reported. Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy (2017) · Cochrane All outcomes | RR 1.45 [1.13, 1.86] | 1 study · 175 participants | GRADE not reported |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes | 2016-09 | Not listed | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.